Voya Investment Management LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Voya Investment Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 17.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 153,834 shares of the biopharmaceutical company's stock after selling 33,446 shares during the quarter. Voya Investment Management LLC owned 0.14% of Regeneron Pharmaceuticals worth $109,581,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Pamalican Asset Management Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $4,915,000. Intact Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $356,000. Rhenman & Partners Asset Management AB boosted its holdings in Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. increased its position in shares of Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of research reports. The Goldman Sachs Group lowered their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Finally, Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $945.32.

Regeneron Pharmaceuticals Stock Up 1.4 %

NASDAQ:REGN traded up $8.22 during midday trading on Monday, hitting $610.86. 1,175,211 shares of the company were exchanged, compared to its average volume of 726,457. The company has a market capitalization of $66.78 billion, a PE ratio of 15.96, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a fifty day simple moving average of $637.38 and a 200 day simple moving average of $721.91. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the firm earned $11.86 earnings per share. The firm's revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.